Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])

NCT03517449 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

827

Enrollment

INDUSTRY

Sponsor class

Conditions

Endometrial Neoplasms

Interventions

DRUG: Pembrolizumab
DRUG: Lenvatinib
DRUG: Paclitaxel
DRUG: Doxorubicin

Sponsor

Eisai Inc.

Collaborators

[object Object]